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Cell-penetrating Alphabody protein scaffolds 
for intracellular drug targeting
Erwin Pannecoucke1,2*, Maaike Van Trimpont3,4*, Johan Desmet5, Tim Pieters3,4,  
Lindy Reunes3,4, Lisa Demoen3,4, Marnik Vuylsteke6, Stefan Loverix5, Karen Vandenbroucke5, 
Philippe Alard5, Paula Henderikx5, Sabrina Deroo5, Franky Baatz5, Eric Lorent5,  
Sophie Thiolloy5, Klaartje Somers5†, Yvonne McGrath5, Pieter Van Vlierberghe3,4, 
Ignace Lasters5‡, Savvas N. Savvides1,2‡
The therapeutic scope of antibody and nonantibody protein scaffolds is still prohibitively limited against intracellu-
lar drug targets. Here, we demonstrate that the Alphabody scaffold can be engineered into a cell-penetrating pro-
tein antagonist against induced myeloid leukemia cell differentiation protein MCL-1, an intracellular target in 
cancer, by grafting the critical B-cell lymphoma 2 homology 3 helix of MCL-1 onto the Alphabody and tagging the 
scaffold’s termini with designed cell-penetration polypeptides. Introduction of an albumin-binding moiety extend-
ed the serum half-life of the engineered Alphabody to therapeutically relevant levels, and administration thereof in 
mouse tumor xenografts based on myeloma cell lines reduced tumor burden. Crystal structures of such a designed 
Alphabody in complex with MCL-1 and serum albumin provided the structural blueprint of the applied design prin-
ciples. Collectively, we provide proof of concept for the use of Alphabodies against intracellular disease mediators, 
which, to date, have remained in the realm of small-molecule therapeutics.
INTRODUCTION
Monoclonal antibodies are currently at the forefront of clinical treat-
ments for various cancers, infections, and (auto)immune diseases 
and represent 7 of the top 10 best-selling drugs worldwide in 2018 
(1, 2). Although therapeutic monoclonal antibodies are endowed by 
many favorable characteristics that are important for their use as 
therapeutic agents, such as long serum half-life, high specificity, and 
immunological effector functions, they are also critically limited by 
low tissue penetration and inability to directly address intracellular 
drug targets. In addition, they impose high production or formula-
tion costs due to low stability and the need for essential posttranslational 
modifications and harbor complexities in drug administration and 
patient care. To overcome some of these impediments, alternative 
approaches emerged, including engineered antibody fragments, such 
as the recently Food and Drug Administration–approved caplacizumab 
(3), as well as nonantibody protein scaffolds (4, 5). Interest in non- 
immunoglobulin (Ig) protein scaffolds has been particularly intense 
because of the ease of screening and selection of high-affinity bind-
ers, exquisite stability, scalability, and low cost of production. How-
ever, despite successes in preclinical studies, the progression of 
nonantibody scaffolds to clinical development is often hampered by 
the limited serum half-life of these small-sized protein scaffolds 
and, similar to antibodies, their inability to reach intracellular tar-
gets (4–6).
In this study, we sought to develop the Alphabody as a non-Ig pro-
tein scaffold that may help to address these challenges in drug discov-
ery and development. Alphabodies are based on a single- chain non-Ig 
protein scaffold featuring an antiparallel triple-helix coiled-coil fold 
(Fig. 1A) (7). The three helices are each composed of four heptad 
repeats with tightly packed isoleucines at core positions (a and d) in a 
regular “knobs-into-holes” configuration. This all-Ile core endows the 
Alphabody with exceptional thermal stability (TM of about 120°C), 
while allowing for up to 25–amino acid positions that can be varied for 
the purpose of constructing a binding site to the intended molecular 
target (7). Previously, we developed Alphabodies that act as potent an-
tagonists of the proinflammatory cytokine interleukin-23 (IL-23) (7, 8), 
an extracellular protein target of clinical importance (8, 9). Here, we 
engineered Alphabodies to target an intracellular tumorigenic protein, 
induced myeloid leukemia cell differentiation protein (MCL-1). MCL-1 
is a member of the antiapoptotic B-cell lymphoma 2 (BCL-2) family, 
a group of intracellular antiapoptotic proteins that contain up to four 
BCL-2 homology (BH) regions. All members of this family are charac-
terized by their antagonism of apoptosis-initiating proteins, such as the 
pore-forming proapoptotic BCL-2 family members BAK and BAX 
(10–12). Under normal conditions, programmed cell death is counter-
acted by antiapoptotic proteins, such as MCL-1 and BCL-2. However, upon 
cellular stress, the proapoptotic BH3-only proteins are up-regulated 
and bind to proapoptotic BCL-2 family members by docking of the 
BH3-only domain into a hydrophobic groove at the surface of the BCL-
2 family member (13, 14). This interaction results in activation of BAK 
and BAX that will initiate the programmed cell death cascade by 
permeabilization of the mitochondrial outer membrane.
Many tumors prevent apoptosis by the up-regulation of the an-
tiapoptotic protein MCL-1, which makes it an attractive candidate 
for anticancer therapy (15–21). Flavopiridol, a pan-cyclin–depen-
dent kinase inhibitor, and AZD-4573, a selective cyclin-dependent 
kinase 9 inhibitor, have been developed to indirectly down-regulate 
MCL-1. In addition, chemotherapeutics such as anthracyclines are 
known to repress MCL-1 transcription, but all are associated with 
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considerable side effects limiting their therapeutic potential (22–30). 
So far, none of the more than 20 compounds evaluated in preclini-
cal studies or clinical trials have resulted in the approval of an MCL-1–
targeted therapy, despite its clear correlation with therapy resistance 
in various cancers (20, 21, 31).
In the present study, we report the de novo design of a cell-penetrating 
Alphabody (CPAB) able to bind to intracellular MCL-1 with high 
affinity to achieve inhibition. First, we grafted the MCL-1–inhibiting 
BH3 helix onto the Alphabody template, an endeavor requiring the 
application of negative design principles facilitated by the high sta-
bility of the generic Alphabody scaffold. Next, we designed and op-
timized cell penetration tags allowing efficient cellular uptake without 
affecting target binding properties. Last, we extended the serum 
half-life of this MCL-1–targeting Alphabody by grafting a minimal 
Fig. 1. Grafting of the MCL-1–inhibiting motif onto the Alphabody scaffold. (A) Overview of the Alphabody scaffold. Alphabodies are antiparallel triple-helix coiled 
coils consisting of four heptad repeats in each of the three helical elements. Hydrophobic core interactions between isoleucines at positions a and d of each heptad sta-
bilize the fold and result in an extremely high thermal stability and other favorable physicochemical parameters (7). Top: Linear representation of one helix. Bottom: 
Cross-sectional helical wheel representation of the interaction between core positions in the coiled coil. Positions within a triangle at the interface of the three helices 
belong to the same core layer. (B) Six residues (stick representation) describe the MCL-1 (surface representation, red is more hydrophobic)–binding motif to the BH3-binding 
groove. Figure was generated using Protein Data Bank (PDB) code 3MK8. (C) Incorporation of the MCL-1 inhibitory footprint onto the Alphabody scaffold required a polar 
core layer. Top: Six MCL-1 key binding residues (green background) were grafted onto helix B of CMPX-152A, which inserted Aspn+5 (orange) into the all-Ile Alphabody 
core on position d of the third heptad of helix B (B3d, indicated). To maintain structural stability of CMPX-152A, the Ile at position a of the second heptad of helix A (A2a, 
indicated) was substituted for a threonine (orange background). Bottom: Schematic cross section of CMPX-152A showing the AspB3d-containing core layer. Modeling 
revealed that the most stable conformation of an Alphabody clusters ThrA2a and AspB3d into the same core layer (orange triangle). (D) Determination by solution 
enzyme-linked immunosorbent assay (ELISA) of the 8 pM affinity of Alphabody CMPX-152A for MCL-1 (n = 23) (84). (E) Secondary structure characterization in CMPX-152A 
by circular dichroism revealing an all -helical content (n = 1). (F) Representative TM determination experiment of CMPX-152A by circular dichroism thermal denaturation 
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albumin-binding moiety to its remaining variable positions. The 
resulting Alphabody, named CMPX-383B, demonstrates the high 
level of protein engineering tolerated by the Alphabody scaffold and 
sets the stage for the use of Alphabodies in disrupting intracellular 
protein-protein interactions.
RESULTS
Alphabody CMPX-152A integrates the MCL-1 BH3 binding 
principles into a designed protein scaffold
The Alphabody protein scaffold consists of a contiguous polypep-
tide that folds into a three-helix coiled coil with antiparallel helix 
topology, and its entire scaffold surface can be deployed to generate 
a binding surface for a given target (Fig. 1A) (7). To explore the poten-
tial of the Alphabody platform for tailored binding to intracellular 
targets, we sought to neutralize MCL-1, a member of the antiapoptotic 
BCL-2 family and a clinically validated drug target. It has previous-
ly been described that the BH3 helix of MCL-1, when expressed as a 
standalone molecular entity, becomes a high-affinity inhibitor of 
MCL-1 (14). We hypothesized that MCL-1–interacting residues could 
be engrafted onto one of the Alphabody  helices to yield a designed 
Alphabody that can bind to MCL-1 with high affinity and specificity. 
On the basis of the available complexes of MCL-1 and different in-
hibitory peptides (table S1), we selected six residues that were hy-
pothesized to play a key role in the specific binding to MCL-1 (Fig. 1B). 
Together, these residues were positioned to form an amphipathic 
helical element with hydrophobic residues (Leun, Valn+3, and Valn+7) 
on one face and Argn+1/Aspn+5 projecting a polar helical face. In addi-
tion, Glyn+4 was identified as a key determinant for MCL-1 binding, 
as any residue with a side chain larger than that of alanine would 
likely sterically impede MCL-1 binding.
We engrafted these six amino acids onto the B helix of the Al-
phabody scaffold to yield Alphabody CMPX-152A as a prototype. 
In silico docking experiments revealed that incorporation of the MCL-1 
inhibitory footprint into the Alphabody template required grafting 
of the Valn+3Glyn+4Aspn+5 sequence on heptad positions bcd (Fig. 1C, 
green background, and fig. S1). However, this resulted in the inser-
tion of a negatively charged aspartate residue into the hydrophobic 
all-isoleucine core of the Alphabody, which would be expected to 
compromise the stability of the Alphabody. In the absence of op-
tions to engineer interactions that electrostatically stabilize this so-
called “Asp in core,” we applied a negative design methodology that, 
per design, averted the Alphabody from adopting undesired confor-
mations, such as possible oligomeric species or aggregates (32, 33). 
To do so, we further destabilized the AspB3d-containing core layer 
(Fig. 1C, orange triangle) by substituting IleA2a by a threonine (Fig. 1C, 
orange background). The rationale for choosing a threonine residue 
for this purpose was twofold. First, the amphipathic nature of this 
residue would allow both a polar interaction with the core aspartate 
(Fig. 1C, orange triangle) mediated by its hydroxyl group, while its 
hydrophobic methyl group would be able to interface with the adja-
cent all-isoleucine core layer (Fig. 1C, gray triangle). Second, thre-
onine is the only naturally occurring amino acid that combines a 
polar group with an isoleucine-like C-branched configuration, which 
was considered advantageous for replacing an Ile in the Alphabody 
core. Although the energetic penalty of the Asp in core would be 
worsened by this additional polar residue in the Alphabody core, 
in silico modeling revealed that conformations that do not cluster 
AspB3d and ThrA2a into the same core layer (Fig. 1C, orange triangle) 
would be even more unstable and thus more unlikely to form. 
Hence, we actively engineered against any other conformation than 
the desired one.
The resulting Alphabody CMPX-152A showed ultrahigh affinity 
for MCL-1, with a KD = 8 pM (Fig. 1D). This low-picomolar affinity 
proved to be maintained throughout next generations of Alphabodies 
(table S2) and could be orthogonally confirmed for the last generation. 
Circular dichroism measurements confirmed that CMPX-152A 
contained the expected amount of helical secondary structure, yet, 
as expected, the destabilization of a core layer in its fold induced a 
substantial reduction in thermal stability as compared to the Alpha-
body template [TM of 58° and 120°C, respectively, in the presence of 
1 M guanidine hydrochloride (GuHCl)] (Fig. 1, E and F) (7). How-
ever, with a higher than 90% reversible thermal stability in the pres-
ence of a chaotrope (table S3), CMPX-152A is more thermostable 
than the average mesostable protein (TM of 54°C in the absence of 
GuHCl) (34).
Reformatting of anti–MCL-1 Alphabodies to enable cell 
penetration and intracellular protein inhibition
Given the intracellular localization of MCL-1, we developed a sec-
ond generation of MCL-1 inhibitory Alphabodies that can be taken 
up by cells, thereby setting the stage for addressing a fundamental 
challenge in the targeting of intracellular drug targets by protein 
therapeutics. The mechanism of how particular sequences endow 
peptides with cell-penetrating capacities is still under debate. Never-
theless, it has been recognized that naturally occurring cell-penetrating 
sequences, such as TAT, penetratin, and the synthetic peptide cFR4, 
mediate cell penetration by the presentation of guanidium groups 
to the negatively charged phospholipid bilayer (35–40). We lever-
aged these insights to develop reformatted Alphabodies that can 
translocate across the cell membrane without compromising their 
target binding properties. The developed CPAB tag consists of seven 
consecutive arginine-proline repeats ([RP]7) that were engineered 
to be added cotranslationally at the N and C terminus of the Alpha-
body polypeptide (Fig. 2A). The rationale for the choice of a proline 
residue flanked by arginines was twofold. On the basis of currently 
known cell-penetrating peptides, we inferred that a proline residue 
would increase uptake by reducing the electrostatic repulsion be-
tween the protein backbone amides and the lipid bilayer. Further-
more, the hydrophobic nature of a proline residue was expected to 
enhance the efficiency of cell penetration.
Alphabody CMPX-321A carrying CPAB tags at its N and C ter-
minus (Fig. 2A) was found to efficiently cross the mammalian cell 
membrane (Fig. 2, B and C). Specifically, we evaluated this newly 
acquired property by incubating NCI-H929 cells with CMPX-321A, 
followed by probing their cytosolic content for the presence of the 
Alphabody using antibodies recognizing the B helix of CMPX-321A 
(Fig. 2B). After a 2-hour incubation with 2 M added Alphabody, 
the detected signal for CMPX-321A in the cytosolic compartment 
(Fig. 2B, last lane, and fig. S2) exceeded the intensity of the 10-pmol 
reference (Fig. 2B, second lane), implying a cytosolic concentration 
of at least 17 M. The CPAB cellular uptake was further confirmed 
by immunofluorescence in HeLa cells that were treated for 30 min 
with CMPX-321A, followed by detection of this Alphabody using an 
anti-V5 antibody (Fig. 2C, green color). This observation is in con-
trast to previous experiments, in which no signal for a non-CPAB–
formatted control Alphabody could be detected in the cytosol of 
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penetration is independent of the presence of an intracellular protein 
target (fig. S3). Together, our data demonstrate that CPAB format-
ting of CMPX-152A resulted in an MCL-1–binding Alphabody that 
efficiently crosses the mammalian cell membrane, without affecting 
the stability of the Alphabody scaffold or its ability to bind to MCL-1 
(tables S2 and S3). To our knowledge, this is the first known exam-
ple of a cell-penetrating protein scaffold able to efficiently reach the 
intracellular space for binding to a therapeutically relevant pro-
tein target.
To evaluate the therapeutic potential of CPABs, we initially screened 
a panel of MCL-1–dependent cell lines with the CPAB-formatted 
CMPX-321A Alphabody targeting MCL-1. We found that several 
multiple myeloma (MM) cell lines displayed a high sensitivity to 
CMPX-321A treatment [IC50 (median inhibitory concentration) of 
<2 M], while other cell lines—including colorectal, non–small cell 
lung, hepatocellular, ovarian, and acute myeloid cancer cell lines—
were only moderately sensitive or not sensitive at all to MCL-1 inhi-
bition using this anti–MCL-1 CPAB. The high sensitivity of MM 
cells to MCL-1 inhibition mediated by CMPX-321A appeared to 
positively correlate with MCL-1 expression levels. A survey of RNA 
expression data from the Broad Institute Cancer Cell Line Encyclo-
pedia (Entrez ID 4170, accessed 29 March 2020) (41, 42) shows that 
the expression levels of MCL-1 in MM cells is significantly higher 
than in other cancer types (Fig. 2D).
These findings prompted us to investigate the cell killing poten-
tial of the MCL-1 neutralizing Alphabody against a panel of 33 MM 
cell lines (Fig. 2E). Thirteen MM cell lines from this panel were highly 
sensitive to CMPX-321A, with IC50 values in the submicromolar 
range and with NCI-H929 being the most sensitive (IC50 value of 
0.34 M). In addition, 10 MM cell lines showed moderate sensitivity 
Fig. 2. CPAB-formatted CMPX-321A Alphabody efficiently enters MM cell lines to elicit MCL-1 inhibition. (A) Addition of an N- and C-terminal arginine-proline 
([RP]7) tag allows bilayer phospholipid crossing of CMPX-321A, the CPAB-formatted successor of CMPX-152A. (B) Western blot of the rest fraction (RF) and cytosolic fraction 
(CF) of NCI-H929 cells after 2 hours of incubation with 2 M of the CPAB CMPX-321A. (C) Overlay of immunofluorescence experiments confirming the cell-penetrating 
capacity of CMPX-321A (green) in HeLa cells, after 30 min of incubation with 1 M Alphabody. Nuclei are stained with Ruby stain (red). (D) RNA expression data (41, 42) 
show that MCL-1 is substantially more expressed in MM cells compared to other cancer cell types, indicating that this cancer cell type might be MCL-1 dependent. (E) The 
cell killing potential of CMPX-321A was evaluated via a panel of 33 MM cell lines. Thirteen MM cell lines were shown to be very sensitive toward MCL-1 inhibition (IC50 < 1 M), 
10 cell lines were moderately sensitive (IC50 = 1 to 2 M), and 6 cell lines were not sensitive to unresponsive (IC50 > 2 M). (F) The cell killing potency of CMPX-321A cannot 









Pannecoucke et al., Sci. Adv. 2021; 7 : eabe1682     26 March 2021
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
5 of 17
(IC50 values of 1 to 2 M), while 6 MM cell lines showed a weaker 
(IC50 values of 2 to 3.31 M) or no response (IC50 value of 5.03 M) 
to CMPX-321A treatment. Four cell lines were excluded from the 
experiment because they showed a high cell killing percentage (>40%) 
when treated with the non–MCL-1–binding CPAB-formatted pro-
totypical Alphabody CMPX-322M, which is not expected to bind 
specifically to a known protein partner. MM can be divided in dif-
ferent genetic subsets based on their molecular profile, and the kill-
ing potential of CMPX-321A did not appear to be restricted to a 
specific genetic subset, indicating that all MM subgroups could benefit 
from MCL-1 inhibition (Fig. 2F). Together, our data suggest that 
the observed cell death of MM cell lines, induced by CMPX-321A in 
a concentration-dependent manner, is a consequence of MCL-1–
driven inhibition.
Treatment with CPAB CMPX-321A induces BAK activation 
followed by apoptosis
Next, we sought to confirm that the cell killing effect in MM cell 
lines was mediated by cellular apoptosis. Using flow cytometry, we 
show that the observed cell death in NCI-H929 cells induced by 
CMPX-321A occurs via a dose-dependent activation of BAK, which 
is generally considered a hallmark event in apoptosis (Fig. 3B). To 
further confirm that the CMPX-321A–induced cell death was a con-
sequence of BAK-mediated apoptosis, we performed additional 
propidium iodide (PI)/annexin V flow cytometry experiments in 
SU-DHL-4 cells. These cells were treated in triplicate for 6 hours 
with vehicle, CMPX-322M (2.5 to 5 M), or CMPX-321A (2.5 to 
5 M) (Fig. 3C). The results show that the non–MCL-1 CPAB CMPX-
322M induces apoptosis in only a minor fraction of the cells, while 
the MCL-1–targeting CPAB CMPX-321A induces a high percent-
age of apoptosis compared to the vehicle only (P = 0.0032). Upon 
CMPX-321A treatment (5 M), a statistically higher percentage 
of apoptotic cells is observed compared to the cells that were treated 
with 2.5 and 5 M of the control CMPX-322M (P  =  0.0167 and 
P = 0.02, respectively) (Fig. 3, D and E). This clearly demonstrates 
that CMPX-321A induces BAK-driven cell death. To our knowl-
edge, Alphabody CMPX-321A is the first non-Ig protein scaffold 
capable of translocating across a mammalian cell membrane to neu-
tralize an intracellular target and to elicit a therapeutically rele-
vant outcome.
Albumin binding increases serum half-life of CMPX-321A 
without compromising cell penetration
Because of their typical molecular weight of about 18 kDa, in vivo 
administered CPAB Alphabodies would be expected to undergo fast 
renal clearing, suggesting a need to increase their serum half-life to 
a therapeutically suitable window. Being aware that an increase in 
molecular weight could impede efficient cell penetration, we lever-
aged the crystal structure of Finegoldia magna protein G to engineer 
a minimal albumin-binding site (Fig. 4A) (43). F. magna protein G 
features a three-helix bundle fold, in which only the two shorter 
C-terminal  helices are involved in albumin binding. Substitution 
of the larger  helix of protein G by the C helix of CMPX-321A al-
lowed engineering of an albumin-binding site with only a modest 
increase in molecular weight by 3.6 kDa. Last, we engineered a di-
sulfide bond to tether the two albumin-binding helices to the Al-
phabody’s C helix to enhance stability. The resulting Alphabody 
CMPX-383B combines the functionality of CMPX-321A with albumin- 
mediated half-life extension (HLE) technology, while retaining thermal 
stability and target affinity (tables S2 and S3). Biolayer interferometry 
(BLI) experiments further revealed that an exceptionally low dis-
sociation velocity constant (kd) is at the root of this ultrahigh affinity 
consistent with the expected hydrophobic nature of the interaction 
(Fig. 4B).
We reasoned that the affinity of the Alphabody for albumin should 
be carefully tuned to allow for albumin release before translocation 
into the cell. Initial immunofluorescence experiments in the pres-
ence of mouse serum albumin (MSA) revealed that a too high affin-
ity for MSA impeded timely crossing of the lipid bilayer (Fig. 4D, 
right column). However, by substituting Gly40 in CMPX-383B for 
Ala, we were able to achieve a 40-fold reduction in the affinity of the 
Alphabody for serum albumin (KD = 7.5 nM versus KD = 310 nM; 
table S2). Whereas cellular uptake of CMPX-383B in the presence of 
MSA was slower compared to CMPX-321A (Fig. 4D, left column), this 
effect gradually diminished over time until the 16-hour time point, 
where no differences in cellular uptake could be observed (Fig. 4B, 
third row). Thus, it appears that albumin binding slows down, but 
does not prevent, the cellular uptake of the Alphabodies.
The effectiveness of HLE technology to extend the serum half-
life of Alphabodies was confirmed by performing a pharmacokinetic 
study of administered Alphabody serum concentrations in healthy 
mice. CD-1 and CB-17 severe combined immunodeficient (SCID) 
mice were treated with a single intravenously administered bolus 
injection at 20 mg/kg of CMPX-321A and the half-life extended 
CMPX-383B, respectively. For both studies, Alphabody concentra-
tions in serum and tissue samples were quantified using an in-house–
developed solution enzyme-linked immunosorbent assay (ELISA) 
assay, which quantifies the concentration of intact and functionally 
active Alphabody in the samples. Measurement of serum levels demon-
strated that the addition of HLE technology to the Alphabody sub-
stantially delays serum clearance (Fig. 4C). The calculated half-life 
(t1/2) of CMPX-383B was 76 min, which was 10-fold higher than the 
t1/2 of CMPX-321A (t1/2 of 7.6 min).
CMPX-383B reduces tumor burden in MM xenograft 
models in vivo
To further probe the efficacy of Alphabodies with HLE optimization 
in vivo, we tested the effect of CMPX-383B in xenograft mice tumor 
models using MM cells. In a first series of xenograft experiments, two 
highly sensitive human MM cell lines NCI-H929 and MOLP-8 (in 
vitro IC50 for CMPX-383B of 0.45 and 0.82 M, respectively) were 
subcutaneously injected in nonobese diabetic/SCID  (NSG) mice 
(n = 20) (Fig. 5, A to C). Once the tumors reached an average vol-
ume of 80 mm3 (range between 50 and 100 mm3), treatment with 
CMPX-383B (n  =  10) or vehicle control (n  =  10) was initiated. 
CMPX-383B was administered once daily by intravenous injection 
at 20 mg/kg for 14 days (Fig. 5A). Daily administration of CMPX-
383B (20 mg/kg) appeared to be well tolerated by the mice, and no 
toxic side effects by Alphabody CMPX-383B could be observed. During 
treatment, a significant delay in tumor growth was observed in the 
CPMX-383B–treated group compared to vehicle-treated mice in both 
NCI-H929 and MOLP-8 xenograft models (P = 0.002 and P = 0.007, 
respectively) (Fig. 5, B and C). Further monitoring after stopping 
the treatment in MOLP-8 xenografts revealed a near-significant pro-
longed delay in tumor growth during the week after the last treat-
ment (P  =  0.051) (fig. S1). In conclusion, our data show that 
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Fig. 3. CPAB CMPX-321A induces BAK-mediated apoptosis. (A) Flow cytometric histograms showing overlay plots of NCI-H929 cells treated with control CPAB CMPX-322M 
(green) and anti–MCL-1 CPAB CMPX-321A (red) that have been stained with an antibody specifically recognizing activated BAK (n = 2). (B) Percentage of BAK-activated–
positive NCI-H929 cells following CPAB treatment with anti–MCL-1 CPAB CMPX-321A (red) and control CPAB CMPX-322M (green). CMPX-321A induces a dose-dependent 
BAK activation. The control CPAB is not inducing BAK activation and is comparable to nontreated cells (n = 2; error bars represent the SEM). (C) Two-dimensional dot plots 
showing SUD-HL-4 cells after 6 hours of treatment with vehicle, CMPX-322M (2.5 to 5 M), or CMPX-321A (2.5 to 5 M) after annexin V fluorescein isothiocyanate (FITC)/
PI staining. These plots show four regions corresponding to early apoptotic cells (PI-/FITC+; Q1), late apoptotic cells (PI+/FITC+; Q2), necrotic cells (PI+/FITC-; Q3), and viable 
cells (PI-/FITC-; Q4). A higher percentage of apoptotic cells are observed after CMPX-321A treatment compared to the vehicle or CMPX-322M control. (D) Upon CMPX-
321A treatment (5 M), a statistically higher percentage of apoptotic cells is observed compared to the cells that were treated with 2.5 and 5 M of the control CMPX-322M 
[P = 0.0167 and P = 0.02, respectively; one-way analysis of variance (ANOVA)] *: P ≤ 0.05. **, P ≤ 0.01. (E) Bar charts showing the mean percentage of necrotic, dead, apop-
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Structural basis of MCL-1 inhibition by CMPX-383B 
and of Alphabody HLE in serum
We pursued structural studies of CMPX-383B in complex with ei-
ther MCL-1 or human serum albumin (HSA) by x-ray crystallography 
to elucidate the structural basis of the various design principles that 
were applied toward developing a CPAB with specificity for intra-
cellular MCL-1 and favorable serum half-life. For our structural stud-
ies using MCL-1, we expressed and purified recombinant NCMCL-1 
(residues 172 to 320), a minimal construct that contains the BH3- 
binding groove and which results in higher protein expression 
and stability (14). A critical step in the biochemical isolation of the 
NCMCL-1:CMPX-383B complex concerned the mixing of bacterial 
cell lysates after expression of the two proteins independently. The 
structural undertakings involving HSA used a second variant of 
CMPX-383B featuring an alternative implementation of the polar 
core layer. Purified and monodisperse protein samples for NCMCL-1: 
CMPX-383B and HSA:CMPX-383B complexes led to optimized crys-
tals that diffracted synchrotron x-rays to 2.26 and 3.3 Å, respectively 
(Table 1 and Fig. 6).
The crystal structure of the NCMCL-1:CMPX-383B complex 
revealed the structural basis of MCL-1 inhibition and how CMPX-
383B structurally accommodates for the negative design elements 
featuring a polar core layer (Fig. 6). To engage MCL-1, CMPX-383B 
deploys only the B helix to bind at the BH3-binding groove of MCL-1 
(Fig. 6), which is presented by helices 2, 3, and 4 of MCL-1. The 
six MCL-1 residues that were grafted onto the B helix of CMPX-383B 
form the epicenter of the interaction, of which four make direct 
contacts with the hydrophobic platform of MCL-1 (Fig. 6A), while 
AspB3d and ArgB2g of the Alphabody electrostatically interact with 
Arg263 and Asn260, respectively, and the backbone of His152 and Val153 
of NCMCL-1 (Fig. 6B). The binding of the CMPX-383B B helix is 
further secured by interactions at both termini mediated by Glu49, 
Lys52, and Tyr70, which seal the MCL-1 groove otherwise used to 
sequester antiapoptotic mediators. The B helix of CMPX-383B su-
perimposes very well with the structure of the inhibitory MCL-1 
helix SAHBD in complex with MCL-1 [root mean square deviation 
(RMSD) of 0.713 Å for 17 aligned C atoms] (Fig. 6G), including 
the hallmark arching imposed onto the inhibiting helix by MCL-1 
(Fig. 6, E and F). The MCL-1–binding B helix of CMPX-383B dis-
plays a curvature of almost 30° toward its C terminus that coincides 
with a slight widening of the Alphabody core initiated at the polar 
core layer. The engineered polar core layer serves a twofold purpose 
to facilitate interaction of the core AspB3d of CMPX-383B with Arg263 
of NCMCL-1 and to mediate compliance with the conformational 
criteria imposed by the binding target. Collectively, this direct struc-
tural evidence illustrates how the Alphabody scaffold can be tai-
lored to the particular structural landscape of the molecular target 
to bind with high specificity.
The crystal structure of the HSA:CMPX-383B complex allowed 
assessment of the possible structure-function consequences of HLE 
technology for the Alphabody scaffold (Fig. 6). Similar to the graft-
ed MCL-1 inhibitory signature on the B helix, we observed that the 
appended D and E helices of CMPX-383B are virtually superimposable 
with the F. magna protein G template (RMSD of 0.49 Å over 48 C 
atoms) (Fig. 6H), providing direct evidence that the HLE technology 
allows an Alphabody to bind domain II of the albumin molecule 
using an extensive network of electrostatic interactions (Fig. 6, C 
and  D). These interactions are reinforced by the burial of Phe118 
and, to a lesser extent, Leu122 of the Alphabody into a hydrophobic 
pocket of HSA. Together, these two crystallographic structures high-
light the engineerability and modularity of the Alphabody scaffold 
to accommodate tailored binding requirements to enhance phar-
macokinetic performance.
Fig. 4. Engineering of an albumin-binding site in CMPX-321A to increase its 
serum half-life. (A) By grafting only the short albumin-binding helices of F. magna 
protein G (red) on -helix C of CMPX-321A, the resulting CPAB CMPX-383B is capa-
ble of binding albumin at the expense of only a 3.6-kDa increase in molecular weight. 
(B) Fitting of a 1:1 Langmuir binding model (red) to the BLI data traces (black) of the 
interaction CMPX-383B to immobilized glutathione S-transferase (GST)–NCMCL-1, 
plotted as the spectral shift in function of time. Experiment was performed in du-
plicate. (C) Alphabody concentrations of CMPX-321A (blue) and the serum half-life 
extended Alphabody CMPX-383B (orange) in the sera of, respectively, three mice 
and two mice treated with a single intravenously administered bolus injection of 
20 mg/kg. (D) Confocal microscopy experiments on HeLa cells in the presence of 
10 M MSA show that substitution of Gly40 by alanine (right and middle columns, 
respectively) allows a faster cellular uptake. After the indicated incubation time, 
cells were washed and probed for the presence of the Alphabody (green). The re-
sulting immunofluorescence image was overlaid with a Ruby stain for the nuclei 
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DISCUSSION
It is estimated that only 10 to 14% of the druggable genome can be 
targeted by rule-of-five-compliant small molecules (44). As a result, 
protein-based scaffolds have emerged, featuring a higher specificity, 
lower off-target effects, and immunomodulating properties. How-
ever, both antibody- and nonantibody-based drugs lack the ability 
to cross the mammalian phospholipid bilayer, which limits their 
potential therapeutic space to targets that provide an extracellular 
or endosomal-mediated entry point. Our findings presented here 
show that the Alphabody protein scaffold can be designed, engineered, 
and formatted to display favorable serum half-life properties and to 
efficiently translocate across the mammalian cellular membrane to 
antagonize a tumorigenic protein:protein interface.
By aiming to develop Alphabodies targeting the well-known in-
tracellular drug target MCL-1, an antiapoptotic protein up-regulated 
in multiple tumor types and correlated with therapy resistance 
(15–21, 45), our study goes beyond the currently charted protein- 
based drug-targeting landscape. Although therapeutic inhibition of 
MCL-1 has been pursued for more than a decade, MCL-1 has prov-
en to be recalcitrant to targeting by small molecules (30, 46). Our 
design strategy showcases the engrafting of key binding determinants 
inspired from the interaction of MCL-1 with its inhibitory BH3 he-
lix and other peptides onto the variable positions presented by the 
three-helix coiled-coil fold of the Alphabody scaffold. The resulting 
Alphabody CMPX-152A showed ultrahigh affinity in the low pico-
molar range for MCL-1. This tight binding has been postulated as a 
requirement for on-target affinity in MCL-1–dependent cell lines 
and is >20-fold tighter than the reported affinity of S63845, the 
most promising MCL-1 inhibitor to date (KD of S63845, 190 pM) 
(30, 47). The Alphabody achieves this high affinity via synergy of 
two key structural principles: (i) by harnessing fully the hydrophobic 
and electrostatic interaction opportunities presented at the epicenter 
of the BH3-binding groove of MCL-1 and by exploiting additional 
interactions at the ends of the  helix B to seal the BH3-binding 
groove and (ii) by exhibiting plasticity in its B helix to respond to 
the conformational requirements of the target interface. The latter 
feature differentiates this MCL-1–binding Alphabody from previous 
generations of the Alphabody scaffold and suggests that this prop-
erty could be additionally exploited against new targets.
Engraftment of the MCL-1–binding residues onto the Alphabody 
scaffold required implementation of protein negative design mani-
fested via the insertion of an aspartate residue into the hydrophobic 
inner core of the Alphabody and the concomitant engineering of an 
additional threonine in the aspartate-containing core layer, aimed 
to increase the energetic penalty of every other Alphabody confor-
mation above the desired one. Although these negative design prin-
ciples have been proposed to occur naturally during protein 
evolution, for instance, to prevent aggregation and to increase bind-
ing specificity, their application in de novo protein design has been 
limited (32, 48–50).
Arguably, the most far-reaching outcome from our studies has 
been the implementation of a cellular uptake sequence motif that 
can enable efficient translocation of a candidate Alphabody across 
the cell membrane to reach an intracellular target, without loss of 
binding specificity. This addresses the most critical challenge in the 
use of protein scaffolds to reach intracellular drug targets. Initial ex-
ploration of cell-penetrating peptides, including the TAT sequence, at 
either the N or C terminus did not result in satisfactory levels of cell 
penetration. Furthermore, as an arginine residue frequently serves as 
a hotspot for protease recognition, we refrained from using a poly- 
arginine sequence as a tag for cellular uptake. Proline residues are 
hydrophobic by nature and considered to be less susceptible to pro-
teolytic activity, and as initial modeling seemed to indicate that the 
conformational constraints on the peptide backbone could provide a 
Fig. 5. In vivo antitumor effect of CMPX-383B in a MM xenograft model. (A) Therapy schedule followed for the treatment of both MM xenograft models. i.v., intrave-
nously. (B) Treatment of NCI-H929 xenograft mice for 14 days with CMPX-383B (n = 10) significantly decreases tumor volume (TV) growth in CMPX-383B–treated mice, 
compared to vehicle (n = 10, P = 0.002). (C) Treatment of the MOLP-8 xenograft model with CMPX-383B (n = 10) results in a significant decrease in tumor volume growth 
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good clustering of the arginine guanidium groups, we gradually con-
verged onto the [RP]7 tag. Last, although cellular uptake was also possible 
using a single N- or C-terminal CPAB tag, the highest efficiency of cell 
penetration was observed when CPAB sequences were present at both 
termini. We showed that such an anti–MCL-1 Alphabody, when decorat-
ed with CPAB tags, was a potent inhibitor of several MCL-1–dependent 
oncogenic cell lines and induced apoptosis in a dose-dependent 
manner by activating the BAK-dependent mitochondrial apoptotic 
Table 1. Crystallographic data and refinement statistics. Values in parentheses correspond to the highest-resolution shell. RMS, root mean square. 
Protein complex CMPX-383B:NCMCL-1 (PDB 6ZIE) CMPX-383B:HSA (PDB 6ZL1)
Crystallization
Crystallization condition 2% (w/v) PEG 3000 18% (w/v) PEG 3350
0.1 M sodium acetate (pH 5.5) 0.1 M bis-tris (pH 6.8)
0.2 M zinc acetate dihydrate 0.2 M ammonium phosphate
Cryoprotectant 30% (v/v) PEG 400 25% (w/v) PEG 3350, 10% (v/v) glycerol
Data collection
Beamline* ESRF ID23-2 PetraIII-P14
Wavelength (Å)* 0.872899 0.9763
Detector* PILATUS 2M PILATUS 6M-F
Space group* P 61 2 2 C 2 2 21
a, b, c (Å); , ,  (°)* 69.70, 69.70, 261.29; 90, 90, 120 60.69, 231.37, 240.19; 90, 90, 90
Resolution (Å)* 44.33–2.3 (2.38–2.3)* 65.83–3.272 (3.39–3.27)†
Total reflections 156,815 (14,751)* 122,695 (5432)†
Unique reflections 17,663 (1682)* 25,902 (1168)†
Multiplicity 8.9 (8.8)* 4.7 (2.7)†
Spherical completeness (%) 99.68 (97.31)* 91.8 (45.1)†
Ellipsoidal completeness (%) n.a. 91.57 (42.48)†
Mean I/ 14.61 (0.84)* 8.47 (0.52)†
Wilson B-factor (Å2) 55.48‡ 84.53†
R-meas (%) 0.118 (2.519)* 0.118 (2.285)†
CC1/2 (%) 100 (38.8)* 99.7 (18.2)†
Refinement‡
Resolution range (Å) 44.33–2.30 65.83–3.27
Reflections: refinement, cross-validation 17,659 (1677), 1059 (100) 24,554 (1125), 1271 (46)
R-work, R-free 0.2236§, 0.2628§ 0.2445║, 0.2786║
Nonhydrogen atoms 2208 8926
Macromolecules, protein residues 2163, 273 8926, 1352
Ligand atoms, solvent atoms 14, 31 0, 0
RMSbonds (Å), RMSangles (°) 0.012, 1.17 0.013, 1.6
Ramachandran favored, allowed, outliers (%) 97.72, 2.28, 0 91.98, 6.73, 1.29
Rotamer outliers (%) 4.78 9.38
Clashscore 2.96 7.49
Average B-factor (Å2) 39.88 97.99
Macromolecules 39.18 97.99
Ligands 83.37 0
Solvent atoms 69.03 0
TLS groups 2 5
*Values reported by the XDS Program Package.   †Values reported by STARANISO anisotropy & Bayesian estimation server.   ‡Values reported by 
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pathway. Similar to other selective MCL-1 inhibitors (51), treatment 
with a cell-penetrating anti–MCL-1 Alphabody results in a rapid 
induction of cell death via apoptosis in hematological malignancies 
such as MM, leukemia, and lymphoma. Thus, we expect that such 
an approach cannot only be widely applied to Alphabodies developed 
against other intracellular targets but also to other protein scaffolds 
as well. To date, 20 different non-Ig–like scaffolds have been reported 
that are often directed against protein-protein interfaces and find appli-
cations in therapeutics, diagnostics, imaging, and research [reviewed in 
(5, 52, 53)]. Notably, Stefin A Quadruple Mutant-Tracy (SQT) scaffolds 
fused to BH3 sequences of Puma, Bim, Noxa, and Bad have been success-
fully deployed to provide insights into BH3-mediated induction of apop-
tosis (54). However, to our knowledge, none of these scaffold proteins 
has been further engineered to include both cell penetration and HLE 
technology by default. Furthermore, although surface cationization and 
incorporation of polycantionic sequences have been reported to endow 
small proteins such as single-domain antibodies, with cell- penetrating 
capabilities (55–60), their application has, however, been restricted to 
proof-of-concept experiments only, as many therapeutic proteins argu-
ably do not readily tolerate surface cationization (55). However, the re-
cent reporting of an -helical mimic of nuclear factor kappa-B essential 
modulator (NEMO) capable of antagonizing the intracellular interaction 
of NEMO with a viral oncoprotein (61) illustrates that interrogation of 
intracellular targets by exogenously administered protein-based antago-
nists is decisively moving forward. Nevertheless, it is clear that the field is 
still at its infancy when it comes to protein scaffolds that can be tailored 
Fig. 6. Structural validation of the applied engineering strategies. Middle: Structural superposition of crystal structures featuring CMPX-383B (pink) in complex with 
either NCMCL-1 (green) or HSA (orange). Alphabody CMPX-383B is shown in cartoon representation. The linker regions between -helix A and B and between  helices 
B and C are represented as dashed lines. The cysteine disulfide bridge that covalently links  helices E to C (dark orange) is shown in stick representation. NCMCL-1 and 
HSA are shown in surface representation. The BH3-binding groove of NCMCL-1 is colored red. (A) Detailed view of the hydrophobic interface between  helices B of 
CMPX-383B and the BH3-binding groove of NCMCL-1.  Helix B of CMPX-383B is shown as ribbon diagram, and NCMCL-1 is shown in surface representation and col-
ored according to the Eisenberg hydrophobicity scale (red is more hydrophobic). (B) Detailed view of the electrostatic interactions around Asp64 and Arg60 of CMPX-383B 
at the BH3-binding groove of NCMCL-1. (C and D) Detailed views on how CMPX-383B engages HSA using predominantly electrostatic interactions at  helix D, the D-E 
loop, and  helix E. (E and F) Structural superposition of CMPX-383B (pink, canonical helix representation) and the canonical IL-23 binding Alphabody MA12 (yellow; 
cylindrical helix presentation, generated using PDB code 5MJ3), highlighting the distinct arching of  helix B of CMPX-383B allowing a full occupancy of the BH3-binding 
groove of NCMCL-1 (surface representation). (G) Structural superposition of the inhibitory MCL-1 helix SAHBD (green; PDB code 3MK8) with  helix B of CMPX-383B 
(pink), both when in complex with MCL-1 (surface representation). (H) Structural superimposition of the albumin-binding moiety of F. magna protein G (cyan; generated 
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to a variety of extracellular and intracellular binding epitopes via a 
combination of computational design and platform technologies 
comprising biopanning and binder selection.
A second advance from our studies concerns the engineering of 
serum HLE technology onto the Alphabody scaffold without inter-
fering with cell penetration or target binding. The key challenge was 
to achieve extension of the serum half-life of CPAB-formatted Alpha-
bodies, which is typically enhanced by increasing the mass of the 
protein, while maintaining a low molecular weight to preserve effi-
cient cell penetration. We succeeded in resolving this dichotomy by 
grafting, rather than adding, the smallest albumin-binding helices 
of F. magna protein G onto the MCL-1–binding Alphabody CMPX-
383B. In principle, this can be applied to increase the serum half-life 
of other scaffolds as well, although engrafting of the albumin-binding 
domain requires the availability of a helical surface, preferably at 
one of the termini of the polypeptide. A survey of protein scaffolds 
and the advent of deep learning approaches in protein design 
and engineering (52, 62–64) suggest that the grafting of molecular 
properties within a helical protein scaffold, thereby avoiding the 
concatenation of additional protein modules, could find broad 
application.
We have demonstrated the benefit of combining these design 
implementations in Alphabody CMPX-383B by alleviating tumor 
burden in vivo via xenograft experiments based on MM cell lines. 
These findings establish the potential of the Alphabody scaffold in 
antagonizing therapeutically relevant intracellular protein interfaces 
in vivo. Our focus on MCL-1 as a proof of concept for our strategy 
was rooted at the -helical nature of confirmed inhibitors and the 
challenging character of targeting this interface with small molecules. 
Recently, several potent and selective MCL-1 inhibitors have been 
reported, some of which have entered clinical trials (NCT03218683, 
NCT03672695, NCT02979366, NCT02675452, and NCT03797261) 
(65–67). As our study sought to explore the Alphabody’s potential 
within a therapeutically relevant scenario rather than developing a 
novel anticancer drug candidate, we refrained from doing head-to-
head comparisons with known MCL-1 inhibitors.
Last, we are left to wonder about the two orders of magnitude 
difference between the determined binding affinity and observed 
potency of CMPX-383B (KD of 8 pM versus IC50 of 0.5 to 1 M in 
NCI-H929 MM cells). Whereas the affinity of CMPX-383B was de-
termined for free MCL-1, intracellular MCL-1 is always in complex 
with either BIM or BAK at the mitochondrion. If a candidate inhib-
itor should target this complex, then the binding of the inhibitor on 
MCL-1 will depend on the kinetics of BAK/BIM release from MCL-
1 and on the dynamics by which newly transcribed MCL-1 becomes 
available for complex formation with BAK or BIM. The biological 
effect (i.e., cell killing) will be triggered upon reaching a certain lev-
el of target occupancy as determined by the biology of MCL-1. At 
the outset, the concentration of inhibitor may exceed the intrinsic 
KD for the target at the IC50. However, for CMPX-383B, the appar-
ent discrepancy between KD and IC50 appears to be more pronounced 
as compared to a small-molecule MCL-1 inhibitor such as S63845, 
evaluated against the same cell types (47). S63845 shows a KD of ap-
proximately 0.19 nM for human MCL-1 and single-digit nanomolar 
potency against NCI-H929. Hence, there may be other factors, not 
related to the biology of MCL-1, that may explain why one compound 
shows a much higher IC50 as compared to another compound, while 
both exhibit strong target binding. This could be reconciled by dif-
ferences in the intracellular accumulation of the respective inhibitory 
molecules, their intracellular mobility, or the accessibility of the tar-
get binding moieties as affected by cellular compartmentalization 
and cytosolic macromolecular crowding (68–74). In light of molec-
ular size considerations, it would be tempting to suggest that these 
effects might be more pronounced for biologicals, such as CMPX-
383B. However, AMG-176, a small-molecule inhibitor of MCL-1 
(67), also shows a pronounced apparent discrepancy between IC50 
and KD (IC50 of 0.24 M in OPM2 cell viability versus a picomolar 
binding affinity). Hence, it is clear that more comparative research 
will be needed to better understand the role of these parameters in 
the targeting of intracellular proteins and to consolidate binding 
behaviors given a particular molecular and cellular context. Collec-
tively, the work we have presented here provides protein design 
principles, technologies, and proof of concept to enable the integra-
tion of protein scaffolds in strategies to antagonize intracellular 
therapeutic targets.
MATERIALS AND METHODS
Expression and purification of Alphabodies
Alphabodies were recombinantly produced as reported previously 
(7). Briefly, recombinant production of Alphabodies with an N-terminal 
decahistidine tag was performed in BL21(DE3)pLysS cells (Life 
Technologies), grown in Luria-Bertani medium at 37°C. At an opti-
cal density at 600 nm (OD600nm) of 0.6, expression was induced by 
an addition of 1 mM isopropyl--d-thiogalactopyranoside. Expression 
was allowed for 4 hours at 37°C, after which cells were harvested 
by centrifugation, resuspended in tris buffer, and frozen at −80°C. Cell 
lysis was performed by thawing and sonication in the presence of 
deoxyribonuclease I (DNase I) and MgCl2, after which the sus-
pension was cleared by centrifugation at 40,000g. Alphabodies were 
isolated from the soluble fraction using a 5-ml immobilized metal 
affinity chromatography (IMAC) HP Ni Sepharose column (GE 
Healthcare), followed by a polishing and desalting step, performed 
on a Superdex 75 size exclusion column (GE Healthcare) equilibrat-
ed in phosphate- buffered saline (PBS).
Production and purification of recombinant human MCL-1
The reference sequences of the complementary DNA (cDNA) encod-
ing for MCL-1 residues Asp172-Gly327 (NCMCL-1) (NM_001197320.1) 
were synthesized by GeneArt as a cotranslational fusion with gluta-
thione S-transferase (GST) and cloned in the pET42 vector (Novagen). 
The GST–MCL-1 fusion protein was expressed in BL21(DE3)pLysS 
cells (Life Technologies). Cultures were grown at 37°C in LB supple-
mented with kanamycin (100 g/ml). At an OD600nm of 0.6, expression 
was induced by addition of 1 mM isopropylthio--galactoside. Ex-
pression was allowed for 4 hours at 30°C, after which cells were har-
vested by centrifugation, resuspended in PBS buffer, and frozen at 
−80°C. Cell lysis was performed by thawing and sonication in the 
presence of DNase I, MgCl2, and AEBSF Protease Inhibitor (Thermo 
Fisher Scientific), after which the suspension was cleared by centrif-
ugation at 40,000g. Purification of the fusion construct was per-
formed from the soluble fraction using GST Trap FF column (GE 
Healthcare), followed by a polishing step performed on a Superdex 
75 size exclusion column (GE Healthcare) equilibrated in tris buffer.
Solution ELISA assays for MCL-1 affinity determination
A Nunc plate was coated with anti-M13 (1 g/ml; Thermo Fisher 
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was then blocked with 2% skimmed milk in PBS for 2 hours at RT 
while shaking. A proprietary Alphabody-displaying phage with high 
affinity for MCL-1 was added in PBS + 1% bovine serum albumin 
(BSA) for 1  hour at RT while shaking. In parallel with previous 
steps, a mixture of 50 pM GST-tagged MCL-1 and a dilution series 
of test Alphabody (seven twofold dilutions starting at 2 nM plus a 
blank) in PBS + 1% BSA was preincubated in a deep-well plate for 
4 hours at RT. In addition, a “calibrator” dilution series of GST-
tagged MCL-1 (seven twofold dilutions starting at 100 pM plus a 
blank) in PBS  +  1% BSA was prepared. The MCL-1–Alphabody 
mixtures and the calibrator series were then transferred to the ELISA 
plate in duplicate (two columns for each series) and incubated for 
another 1 hour at RT while shaking. Detection of bound GST–MCL-1 
was performed with 1:5000 goat anti–GST–horseradish peroxidase 
(HRP) (Abcam) in PBS + 1% BSA for 30 min at RT while shak-
ing. After each incubation step, the plate was washed 4× with PBS 
containing 0.05% Tween 20, except after the incubation step of 
the mixture and calibrator samples where the plate was washed 
12 times. The plate was developed with SureBlue, and the reaction 
was stopped with H2SO4. ODs were read at 450 nm. For the calcula-
tion of Alphabody–MCL-1 affinity, the OD signals from the cali-
brator series were first fitted to a sigmoid function, the latter 
providing the relationship between the measured ODs and free 
GST–MCL-1. Using this relationship, the OD values measured 
for the Alphabody–MCL-1 mixtures were converted to free GST–
MCL-1 concentrations, and the latter were then fitted to the qua-
dratic equation for Alphabody–MCL-1 binding, using the solution 
KD as parameter.
Solution ELISA assays for albumin affinity determination
An ELISA assay was elaborated for CPAB-albumin affinity deter-
mination exploiting the observation that CPABs show affinity for 
skimmed milk–blocked Nunc plates but not when bound to albu-
min. A Nunc plate was blocked O/N with PBS + 2% skimmed milk 
in PBS at 4°C. A mixture of 8 nM CPAB CMPX-383B and dilution 
series of human, rat or mouse serum albumin was prepared (seven 
threefold dilutions starting at 10 M plus a blank) in 100 mM tris + 
100 mM NaCl + 1% BSA (at pH 7.4) in deep-well plates and pre-
incubated for 30 min at RT while shaking. In addition, a calibrator 
dilution series of CPAB (seven threefold dilutions starting at 100 nM 
plus a blank) in 100 mM tris + 100 mM NaCl + 1% BSA (at pH 7.4) 
was prepared. The albumin-CPAB mixtures and the calibrator 
series were then transferred to the ELISA plate in duplicate (two 
columns for each series) and incubated for another 30  min at RT 
while shaking. Detection of plate-bound CPAB was performed with 
1/5000 anti-V5-HRP (Invitrogen, R961-25) in PBS + 0.1% BSA for 
30 min at RT while shaking. After each incubation step, the plate 
was washed 4× with PBS containing 0.05% Tween 20. All further 
steps, including the conversion of OD values into free CPAB con-
centrations using the calibrator series and the fitting of solution KD 
values, were the same as for MCL-1 affinity determination.
Circular dichroism experiments
Before the measurement, Alphabodies, stored in 20 mM Hepes 
(pH 7.2) and 150 mM NaCl, were centrifuged and diluted to 200 to 
340 g/ml in PBS with indicated concentrations of GuHCl. The 
fraction of -helical content was calculated from the molar residue 
ellipticity (MRE) at 222 nm. For determination of the thermal sta-
bility, the up scan (5° to 95°C) was immediately followed by a down 
scan (95° to 5°C). The reported TM value was calculated as the aver-
age temperature of the two minima. Reported values for reversibil-
ity of folding were calculated as the ratio of MRE at 25°C from the 
down scan versus the up scan.
Western blot analysis of Alphabody cellular  
uptake and determination of intracellular cytosolic 
Alphabody concentrations
NCI-H929 cells were seeded in 12-well plates (Greiner Bio-One, 
#665180) at a density of 6 × 105 cells per well in standard culture 
medium. After overnight growth, either Alphabody CMPX-321A or 
the non-CPAB–formatted Alphabody MB23 was added to a final 
concentration of 2 M and incubated for either 2 or 6 hours at 
37°C. After incubation, the cells were harvested, and their cell content 
was fractionated into a cytosolic and rest fraction (Abcam Cytosol/
Particulate Rapid Separation Kit, #ab65398) and loaded on SDS–
polyacrylamide gel electrophoresis (PAGE) (10% Criterion XT bis-tris 
gel, Bio-Rad) together with a dilution series of CMPX-321A. Pro-
tein content was electroblotted to a 0.2 M polyvinylidene difluo-
ride (PVDF) membrane (Trans-Blot Turbo Midi 0.2-m PVDF, 
Bio-Rad). After blocking and washing, Alphabodies were detected 
using a mix of antibodies (anti-histidine tagged antibody clone HIS.
H8, Merck, #05-949; 1/2000 diluted and supplemented with two 
proprietary monoclonal antibodies recognizing a common epitope 
in the  helix B) and visualized using an anti-mouse alkaline phos-
phatase (AP) secondary antibody (anti-mouse IgG AP conjugate, 
Promega, #S3728; 1/5000 diluted).
The calculation of cytosolic concentration is based on in-house 
confocal microscopy experiments. These allowed us to estimate the 
volume of NCI-H929 cell to be approximately 1 pl. The intensity of 
the CMPX-321A signal in the cytosolic fraction of Fig. 2B was high-
er than the 17 M (10 pmol) calibrator lane. Given that the isolated 
cytosolic fraction of NCI-H929 cells is even lower than the total cell 
volume (in which other organelles, such as the relatively big nucle-
us, are present), we can infer that the intracellular concentration of 
CMPX-321A exceeds 17 M as well.
Immunofluorescence experiments on HeLa cells
HeLa cells were seeded in eight-well Nunc Lab-Tek Chamber Slides 
(Thermo Fisher Scientific, #177402), treated with 1 M MCL-1–targeting 
CPAB in the presence or absence of 10 M MSA for the indicated 
time points. Cells were fixed and permeabilized with 100% methanol 
and blocked with 2% BSA in Dulbecco’s PBS with 0.05% Triton 
X-100 blocking (1 hour at RT), before incubating with anti-V5 tag 
monoclonal (1 hour at RT; Thermo Fisher Scientific, #R960-25). 
Primary antibody was visualized using anti-mouse Alexa Fluor 
488–conjugated antibody (45 min at RT; Thermo Fisher Scientific, 
#A-21202). Vybrant DyeCycle Ruby stain (30 min at RT; Thermo 
Fisher Scientific, #10115414) was used to dye the nuclei. Chambers 
were removed and coverslips mounted with fluorescence mounting 
medium (Dako, #S3023). Images were obtained using a Zeiss LSM 
510 META confocal microscope and analyzed using Fiji ImageJ.
Western blot analysis to determine cytoplasmatic presence 
of CMPX-321A and CMPX-322M in SU-DHL-4 cells
SU-DHL-4 cells were treated in vitro with either vehicle or 1.25, 2.5, 
or 5 M anti–MCL-1 CPAB (CMPX-321A) and a control CPAB 
(CMPX-322M) for 2 hours. After washing the cells with PBS, cell 
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150 mM NaCl, 0.1% NP-40, 2.5 mM MgCl2, and 5% glycerol] and 
lysed for 15 min on ice. Lysates of total protein were separated by 
SDS-PAGE, electrotransferred to nitrocellulose membranes, and 
analyzed for the presence of the Alphabodies using a V5 antibody 
(Invitrogen, R960-25). Protein detection was performed with the 
Chemidoc MP Imager and the Image Lab software.
In vitro treatment of MM cell lines with CMPX-321A
Human myeloma cell lines were derived from primary myeloma cells 
cultured in RPMI 1640 medium supplemented with 5% fetal calf 
serum and recombinant IL-6 (3 ng/ml) for IL-6–dependent cell lines. 
Cell viability was measured using CellTiter-Glo luminescent cell vi-
ability assay from Promega. As control and to calculate percentages 
of cell viability, at least triplicates of cells in medium only (without 
test compound) were included on every plate. Luminescence signal 
of these wells (cells without test compound) corresponds to 100% 
cell viability. The start concentration of CMPX-321A and CMPX-
322M was 5 M with a twofold dilution step and seven concentra-
tion points (5 to 2.5 to 1.25 to 0.625 to 0.313 to 0.156 to 0.078 M). 
As a buffer control, dilutions of buffer corresponding to the seven 
dilutions of test compounds were included. All experiments were 
repeated three times, and each experimental condition, including 
the buffer control, was repeated in duplicate wells in each experi-
ment. The inhibition effect was calculated after 72 hours of incuba-
tion with the following formula: % viability = (luminescence of treated 
cells / luminescence of cells with medium only) × 100. IC50 values 
were calculated using the GraphPad Prism software and a four- 
parameter nonlinear regression with 100% cell survival in medium 
as top constraint and 0% cell survival as bottom constraint.
BAK activation assay
NCI-H929 cells were treated with twofold dilutions starting at 10 M 
CPABs in 500 l of complete cell culture medium containing 10% 
fetal bovine serum. Cells were incubated for 4 hours at 37°C. After 
CPAB treatment, cells were washed with PBS and permeabilized us-
ing the Cytofix/Cytoperm Fixation/Permeabilization Solution Kit 
(BD Biosciences) following the manufacturer’s recommendations. 
Activated BAK was detected with the primary anti-BAK antibody 
TC-100 (Merck Millipore). After a washing step, detection of the 
primary anti-BAK antibody was performed with an Alexa Fluor 
488–labeled secondary anti-mouse antibody. To exclude dead cells 
from data analysis, the LIVE/DEAD Fixable Near-IR Dead Cell Stain 
(Invitrogen) was included. Last, cells were washed once and mea-
sured on a BD LSRFortessa cell analyzer. The flow cytometry data 
were analyzed using either FACSDIVA or FlowJo software.
Annexin V/PI staining
Annexin V/PI double-staining kit (BD Biosciences, 556547) was 
used to detect cell apoptosis via flow cytofluorimetric analysis. 
SUD-HL-4 cells were treated in triplicate for 6 hours with either 
vehicle [20 mM Hepes (pH 7.2) and 150 mM NaCl], CMPX-322M 
(2.5 to 5 M), or CMPX-321A (2.5 to 5 M). After treatment, cells 
were washed with cold PBS, and the protocol of the annexin V/PI 
kit was followed as recommended by the manufacturer. During this 
experiment, unstained, single annexin V and PI stains were included 
for further flow analysis. The data generated by flow cytometry 
were analyzed using the FlowJo software (BD Biosciences) and are 
plotted in two-dimensional dot plots in which annexin V–fluorescein 
isothiocyanate (FITC) is represented versus PI. These plots show four 
regions corresponding to apoptotic cells (PI-/FITC-; Q1), late 
apoptotic cells (PI+/FITC+; Q2), viable cells (PI+/FITC-; Q3), and 
necrotic cells (PI-/FITC-; Q4). Statistical analysis was performed 
using the GraphPad Prism 8.3.0 software [one-way analysis of vari-
ance (ANOVA)].
BLI experiments
BLI experiments were performed at 25°C in kinetic buffer [PBS (pH 7.4), 
0.02% (v/v) Tween 20, and 0.1% (w/v) BSA] using an Octet RED96 
machine (Sartorius). Anti-GST biosensors (Sartorius, 18-5096) were 
functionalized with GST-NCMCL-1, a response shift of 1 nm, and 
dipped into a solution containing indicated concentrations of the 
Alphabody. Nonfunctionalized biosensors were used during the as-
say to determine nonspecific binding of the Alphabodies. Sensor traces 
of zero concentration conditions were used for single reference sub-
traction. A 1:1 ligand model was fitted to all data using the FortéBio 
Data Analysis 9.0.0.4 software. For each experiment, a technical 
replicate was performed.
CMPX-383B test item handling for in vivo experiments
The vials containing the Alphabody CMPX-383B were stored at −80°C 
until the day of use. On the day of use, CMPX-383B was thawed for 
30 min in a water bath at 37°C. Before use, the test substance was 
visually inspected for sign of turbidity. If turbidity was observed, 
then the vial of the test substance was put in the water bath at 37°C 
for another 15 min. The test substance was used within 1 hour of 
thawing for all in vivo experiments.
In vivo treatment of MM xenograft models
A MOLP-8 subcutaneous xenograft model was established in 20 NSG 
female mice at the age of 6 to 8 weeks by injecting 1 × 107 in human 
MM MOLP-8 cells at the right flank region. Before tumor cell inoc-
ulation, each animal was pretreated for 2 days with a daily intraperitoneal 
injection of cyclophosphamide (150 mg/kg) to facilitate engraftment 
of the MOLP-8 cells. Once the tumors reached an average volume 
of 80 mm3 (range between 50 and 100 mm3), mice were randomized 
into two groups and either treated daily with vehicle [20 mM Hepes 
(pH 7.2) and 150 mM NaCl] or CMPX-383B (20 mg/kg of body weight) 
for 14 consecutive days. Tumor volume was measured twice a week 
using a caliper until 20 days after the last treatment administration. 
Mice were closely monitored and euthanized if tumor volume 
reaches 3000 mm3 or any humane end points.
For the NCI-H929 subcutaneous xenograft model, 20 female CB-17 
SCID mice (nomenclature: CB-17/Icr-PrKDcscid/Rj) at the age of 8 weeks 
were subcutaneously inoculated with 5 × 106 NCI-H929 tumor cells 
into their right flank. Tumor volume was measured twice a week by 
caliper, and body weight was determined in parallel. Once an average 
tumor volume of 80 mm3 was reached, animals were randomized into 
two groups. The animals received once daily, repeated intravenous 
doses of CMPX-383B (20 mg/kg) or vehicle [20 mM Hepes (pH 7.2) 
and 150 mM NaCl]. All experiments involving mice were performed by 
the biopharmaceutical company Heidelberg Pharma (Germany), and 
all ethical guidelines were followed as imposed by the European Union.
Statistical analysis of in vivo tumor evolution 
in xenograft models
Special consideration was given to the statistical analysis of the ac-
quired data. Recognizing the presence of correlated observations 
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tumor volumes as longitudinal data, also known as repeated mea-
surements. The defining feature of longitudinal data is the possibil-
ity to characterize changes over time (e.g., tumor progression) and 
factors that influence that change. This is in contrast to the more 
commonly performed analysis at each time point, which only pro-
vides information about the differences in treatment effects at that 
specific time point and hence does not consider the evolution in 
treatment effects. Ordinary linear regression can model the evolu-
tion in outcome over time but does not accommodate for the cor-
relation between observations. Therefore, in repeated-measurements 
analysis, the aim is not only to characterize changes over time and 
factors that influence that change but also to model the correlation 
across time within subjects, to get better estimates of treatment ef-
fects and the error.
We analyzed tumor volumes and hCD45 percentages as repeated 
measurements using the method of residual maximum likelihood, 
as implemented in Genstat version 20. Briefly, a linear mixed model 
(random terms underlined) of the form y = treatment + time + treat-
ment × time + mouse × time was fitted to the longitudinal data. The 
term mouse × time represents the residual error term with depen-
dent errors because the measurements are taken in the same indi-
vidual, causing correlations among observations. Several covariance 
models were fitted to the data to account for the correlation present 
in the data. The autoregressive correlation model of order 1 (AR1) 
with times of measurement set at equal intervals was selected as the 
best fitted model based on the Akaike’s information criterion co-
efficient (AIC) for analysis of tumor volumes. The AR covariance 
model assumes that correlation between observations decays as the 
measurements are collected further apart in time. The first order 
refers to the fact that only recent (t − 1) observations affect the cur-
rent observations made at time point t. The antedependence cor-
relation model of order 1 (ANTE1) with times of measurement set 
at unequal intervals was selected as the best fitted model based on 
the AIC for analysis of hCD45 percentages. The ANTE1 covariance 
model assumes that correlation between observations decays as the 
measurements are collected further apart in time, just like the AR 
covariance model does, but allows for changes in correlation struc-
ture over time. In addition, the ANTE covariance model allows for 
unequal variances across time. The significance of the fixed terms in 
the mixed model was assessed using an approximate F test as imple-
mented in Genstat version 20.
Expression and purification of recombinant protein 
complexes for crystallization
The reference sequences of the cDNA encoding for MCL-1 residues 
Asp172-Gly327 (NCMCL-1) (NM_001197320.1) were synthesized by 
GeneArt and were a gift from Complix N.V. A GST fusion con-
struct was created in which NCMCL-1 was cotranslationally fused 
to GST, separated by a thrombin recognition sequence. The fusion 
construct was cloned in the pET15b vector (Novagen) using Nco I 
and Bam HI restriction sites. In parallel, a construct was created in 
which crystallography optimized variants of CMPX-383B lacking the 
CPAB sequences could be expressed in the pET15b vector with a 
thrombin-removable hexahistine sequence.
For isolation of the NCMCL-1:Alphabody complex, Escherichia 
coli BL21(DE3) strains were transformed with the expression con-
struct of either GST–NCMCL-1 or the Alphabody. Single colonies 
of both plates were used to inoculate 10 ml of LB medium for over-
night growth. Next day, both precultures were used to inoculate 3 liters 
of LB medium per construct. At OD600nm of 0.6, expression was in-
duced with 1 mM isopropyl--d-thiogalactopyranoside final con-
centration. GST–NCMCL-1 was expressed for 4  hours at 28°C, 
after which the bacteria were harvested by centrifugation (6000g for 
15 min at 4°C), and the cellular paste was stored at −80°C. Expres-
sion of the Alphabody was continued overnight. Next day, the bac-
teria expressing the Alphabody were harvested, while the bacterial 
pellet with GST–NCMCL-1 was thawed. Both pellets were resus-
pended in 45 ml of phosphate buffer [300 mM sodium phosphate 
buffer (pH 7.0) and 300 mM NaCl] per liter of expression culture 
and mixed together before cell lysis. The cells were lysed by sonica-
tion on a Q500-220 QSonica sonicator (run time of 4 min with 30-s 
pulses at 80% output interspersed with 30 s of down time) and cen-
trifuged for 30 min at 20,000g. The supernatant of both lysates was 
collected, filtrated through a 0.22-m filter, and mixed. This mixture 
was then lastly applied overnight on two 1-ml GSTrap (GE Health-
care) at a flow speed of 0.1 ml/min. Next day, both columns were 
extensively washed with phosphate buffer, after which 6 U of bi-
otinylated thrombin (Novagen) was injected. After injection, the 
columns were detached and incubated overnight at RT. Next day, 
elution of thrombin-cleaved NCMCL-1, alone or in complex with 
thrombin-cleaved Alphabody, was performed by restoring the flow 
on the GSTrap columns. NCMCL-1:CMPX-383B was lastly separated 
from thrombin and NCMCL-1 alone by size exclusion chromatog-
raphy (SEC; Superdex 75 HR 10/30 column, GE Healthcare), with 
20 mM Hepes (pH 7.4) and 150 mM NaCl as equilibration buffer.
For isolation of Alphabody:HSA complexes, the Alphabody was 
expressed as described above. Subsequent to cell lysis, his-tagged 
Alphabody was captured by IMAC (5-ml HisTrap FF prepacked 
column, GE Healthcare) and polished by SEC (Superdex 75 HR 10/30 
column, GE Healthcare). The complex with HSA (Sigma-Aldrich) 
was assembled and purified via SEC.
Crystal structure determination of the  
NCMCL-1:CMPX-383B complex
NCMCL-1:CMPX-383B was concentrated to 5.1 mg/ml. Commercial 
sparse matrix crystallization screens (Molecular Dimensions, Hampton 
Research, Jena Bioscience) were set up in a vapor-diffusion fashion, 
by mixing 100 nl of protein solution with 100 nl of mother liquor in 
SWISSCI 96-well triple drop plates. Plates were incubated at 294 K. 
After 6 months, crystals were detected under condition C7 of the 
JCSG-plus crystal screen (Jena Bioscience), containing 0.2 M zinc 
acetate dihydrate, 0.1 M sodium acetate (pH 4.5), and 10% (w/v) 
polyethylene glycol (PEG) 3000. These hits could be further optimized 
using gradient optimization in 96-well format and at different tem-
peratures. Crystals diffracting x-rays to 2.3 Å were grown at 287 K 
under a condition containing 0.2 M zinc acetate dihydrate, 0.1 M 
sodium acetate (pH 5.5), and 2% PEG 3000. Before cryo-cooling by 
plunging into liquid nitrogen, these crystals were stepwise cryopro-
tected to contain a final concentration of 30% (v/v) PEG 400. Diffraction 
data were collected at 100 K at the ESRF ID23-2 beamline, Grenoble. 
Diffraction data were indexed, integrated, and scaled using the XDS 
Program Package (75). Initial phases were obtained using maximum- 
likelihood molecular replacement by Phaser from the CCP4 package 
(76, 77) using the crystallographic model of MCL-1 as a search model 
[Protein Data Bank (PDB) code 3MK8] (14). Structure building and 
refinement were performed iteratively using COOT (78), PHENIX (79), 
BUSTER (80), and the PDB-REDO server (81). The Alphabody struc-
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Crystal structure determination of the  
HSA:CMPX-383B complex
Purified HSA:CMPX-383B complex was concentrated to 95 mg/ml. 
Crystallization screens containing 14 to 24% PEG 3350, 0.2 M am-
monium phosphate, and 0.1 M acetate (pH 4.2 to pH 5.6), bis-tris 
(pH 5.8 to pH 7.0), or bis-tris propane (pH 7.0 to pH 9.0) buffer 
were set up in a vapor-diffusion fashion, by mixing 100 nl of protein 
solution with 100 nl of mother liquor in SWISSCI 96-well triple drop 
plates. Plates were incubated at 287, 294, or 310 K. Crystals with a 
plate-like morphology, diffracting x-rays to 3.27 Å, were grown at 
310 K under a condition containing 18% (w/v) PEG 3350, 0.1 M bis-tris 
(pH 6.8), and 0.2 M ammonium phosphate. Before cryo-cooling by 
plunging into liquid nitrogen, these crystals were cryoprotected to 
contain a final concentration of 25% (w/v) PEG 3350 and 10% (v/v) 
glycerol. Diffraction data were collected at 100 K at the P14 micro-
focus beamline at PETRA III, Hamburg. Diffraction data were in-
dexed, integrated, and scaled using the XDS Program Package (75). 
The resulted dataset was truncated and rescaled using the STARANISO 
anisotropy & Bayesian estimation server (82). Initial phases were 
obtained using maximum-likelihood molecular replacement by 
Phaser from the CCP4 package (76, 77) using the crystallographic 
model of HSA as search model (PDB code 4Z69) (83). Structure 
building and refinement were performed iteratively using COOT 
(78), PHENIX (79), BUSTER (80), and the PDB-REDO server (81). 
The Alphabody structure was built and chain-traced from scratch 
into the electron density.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/13/eabe1682/DC1
View/request a protocol for this paper from Bio-protocol.
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